Inhibition by lithium of the nitrergic relaxation of rat anococcygeus muscle.
In the present study, we evaluated the effect of lithium on the nitric oxide (NO)-mediated nonadrenergic noncholinergic (NANC) relaxation of rat anococcygeus muscle. The isolated precontracted (phenylephrine, 7.5 microM) rat anococcygeus muscle were relaxed via electrical field stimulation (5 Hz) in the absence or presence of lithium (0.5, 1, and 5mM) or in tissues excised from ex vivo lithium (600 mg/L in drinking water for 30 days)-treated animals. Effects of the NO synthase (NOS) inhibitor L-NAME (0.03 and 100 microM) or guanylyl cyclase inhibitor ODQ (1 microM) and NO precursor L-arginine (1mM) on relaxations were investigated. Effect of either in vitro (1 and 5mM) or ex vivo lithium treatment on relaxation to the NO donor sodium nitroprusside (SNP; 0.1-1000 microM) was also investigated on phenylephrine-contracted strips. The NANC relaxation was significantly reduced by in vitro (1 and 5mM; up to P<0.01) and ex vivo lithium treatment (P<0.001). L-NAME (100 microM and 1mM) and ODQ (1 and 10 microM) significantly inhibited NANC relaxations in either control or lithium-treated strips. Combination of lithium (0.5mM) with L-NAME (0.03 microM) significantly (P<0.001) reduced the NANC relaxation. Although 1mM l-arginine had no effect on relaxations, it prevented their inhibition by both in vitro (1 and 5mM) and ex vivo lithium of relaxations. SNP produced concentration-dependent relaxation in precontracted rat anococcygeus muscle which was not altered by lithium treatment. Reverse transcription polymerase chain reaction (RT-PCR) revealed a significant increase in the neuronal NOS expression in the anococcygeus muscle of ex vivo lithium-treated animals compared with controls. Our experiments suggested that both ex vivo and in vitro lithium administration attenuated the NO-mediated neurogenic relaxation of isolated rat anococcygeus muscle.
Karimollah
Ali Reza
AR
Department of Pharmacology, School of Medicine, Medical Sciences/University of Tehran, Tehran 13145-784, Iran.
Ghasemi
Mehdi
M
Ghahremani
Mohammad Hossein
MH
Dehpour
Ahmad Reza
AR
D000704:Analysis of Variance; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D004558:Electric Stimulation; D018021:Lithium Chloride / Q000494:pharmacology*; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects* / Q000294:innervation; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D026602:Nitrergic Neurons / Q000187:drug effects* / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism*; D052248:Nitric Oxide Synthase Type I / Q000235:genetics / Q000378:metabolism; D009599:Nitroprusside / Q000494:pharmacology; D010069:Oxadiazoles / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction
C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; D010069:Oxadiazoles; D011810:Quinoxalines; D009599:Nitroprusside; D010656:Phenylephrine; D009569:Nitric Oxide; D001120:Arginine; D052248:Nitric Oxide Synthase Type I; D018021:Lithium Chloride; D019331:NG-Nitroarginine Methyl Ester